Compositions and methods for inhibiting wnt signaling

A composition and polymer technology, applied in the fields of botany equipment and methods, biochemical equipment and methods, chemical instruments and methods, etc., can solve the problem of high disease recurrence rate

Inactive Publication Date: 2019-02-05
CHILDRENS MEDICAL CENT CORP
View PDF24 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Existing antibiotic regimens for CDI are ineffe

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compositions and methods for inhibiting wnt signaling
  • Compositions and methods for inhibiting wnt signaling
  • Compositions and methods for inhibiting wnt signaling

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0185] Genome-wide CRISPR / Cas9 screen reveals Frizzled receptor as the receptor for Clostridium difficile toxin B

[0186] To identify physiologically relevant receptors and other host factors involved in TcdB action, two unbiased genome-wide mutagenesis screens were performed using the CRISPR (clustered regularly interspaced short palindromic repeats) / Cas9 approach. screen) (15, 16). The C-terminal portions of TcdA and TcdB contain a region called the combined repetitive oligopeptide (CROP, Figure 6, panel A), which binds carbohydrates and mediates the binding of toxins to cells (17). Recent studies have shown the existence of additional receptor binding domains besides CROP (18-21). Indeed, a truncated toxin lacking CROP (TcdB 1-1830 ) still induced cell rounding in a variety of cell lines at clinically relevant picotoxin concentrations (Figure 6, panels B-E) (22). Since CROP-carbohydrate interactions can mask the contribution of specific protein receptors, full-length Tc...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present disclosure relates to isolated polypeptides that inhibit Wnt signaling, pharmaceutical compositions comprising the isolated polypeptides, and methods of use thereof. Nucleic acids, cells,and methods of production related to the isolated polypeptides and compositions are also disclosed.

Description

[0001] related application [0002] This application claims the filing date benefit of U.S. Provisional Application Serial No. 62 / 311,381, entitled Compositions and Methods for Inhibiting WNT Signaling, filed March 21, 2016, under 35 U.S.C. § 119, the entire contents of which are incorporated herein by reference. [0003] governmental support [0004] This disclosure was made with government support under grant 1R01NS080833 awarded by the National Institutes of Health. The government has certain rights in this disclosure. Background technique [0005] Clostridium difficile toxin B (TcdB) is a key virulence factor causing diseases associated with Clostridium difficile infection (CDI). In developed countries, CDI is the most common cause of antibiotic-associated diarrhea and the leading cause of gastroenteritis-related death. Existing antibiotic regimens for CDI are ineffective, and the disease has a high relapse rate. Contents of the invention [0006] Clostridium diffici...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C07K14/33C07K19/00C12N15/31C12N15/70C12N15/79
CPCC07K14/33C07K2319/00C07K2319/21C07K2319/23C07K2319/24C07K2319/30C07K2319/31C07K14/71A61P31/04A61P35/00A61K31/095A61K31/41C12N15/62A61K47/6849A61K2300/00C07K16/1282C07K16/22C12N15/85C12N2015/8572
Inventor 董民陶亮
Owner CHILDRENS MEDICAL CENT CORP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap